专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014207556A1 PEPTIDES AND PEPTIDOMIMETICS IN COMBINATION USES AND TREATMENTS FOR CANCER PATIENT SUBPOPULATIONS 审中-公开
标题翻译：组合使用和治疗癌症患者子宫颈癌的方法和方法
公开(公告)号：WO2014207556A1
公开(公告)日：2014-12-31
申请号：PCT/IB2014/001579
申请日：2014-06-24
申请人： CANBAS CO., LTD.
发明人： KAWABE, Takumi , MINE, Naoki , SAITO, Naoya , SAKAKIBARA, Keiichi , SATO, Takuji
IPC分类号： A61K38/00 , A61P35/00
CPC分类号： C07K7/06 , A61K33/24 , A61K38/00 , A61K38/08
摘要： This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compounds of the invention appear to function at least in part by inhibiting G2 cell cycle checkpoint. Thus, invention compounds can be used to inhibit cell growth alone or be used in combination with a nucleic acid damaging treatment to inhibit cell growth.
摘要翻译：本发明提供了可用于治疗细胞增殖性疾病（例如与良性和恶性肿瘤细胞相关的那些）的肽和肽模拟物的化合物。虽然本发明不限于任何特定的机制，但是本发明的化合物至少部分通过抑制G2细胞周期检查点起作用。因此，本发明化合物可用于单独抑制细胞生长或与核酸损伤处理组合使用以抑制细胞生长。

2. 发明申请

WO2009031040A2 COMPOUNDS WITH ANTI-CANCER ACTIVITY 审中-公开
标题翻译：具有抗癌活性的化合物
公开(公告)号：WO2009031040A2
公开(公告)日：2009-03-12
申请号：PCT/IB2008/003036
申请日：2008-04-11
申请人： CANBAS CO., LTD. , KAWABE, Takumi , ISHIGAKI, Machiyo , SATO, Takuji , YAMAMOTO, Sayaka , HASEGAWA, Yoko
发明人： KAWABE, Takumi , ISHIGAKI, Machiyo , SATO, Takuji , YAMAMOTO, Sayaka , HASEGAWA, Yoko
CPC分类号： A61K31/4439 , A61K31/4725 , A61K31/496 , C07D207/452 , C07D207/50 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/14 , C07D417/12
摘要： Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.
摘要翻译：提供了新的取代的吡咯二酮，其抑制细胞，抑制细胞增殖，抑制细胞生长，消除细胞周期G2关卡和/或引起对G2细胞周期停滞的适应。提供了制造和使用本发明化合物的方法。本发明提供了取代的唑二酮以治疗细胞增殖性病症。本发明包括使用取代的唑二酮来选择性杀死或抑制癌细胞而无需其他抗癌治疗。本发明包括使用细胞周期G2-关卡 - 取消取代的吡咯二酮来选择性地使癌细胞对DNA损伤试剂，治疗和/或其他类型的抗癌试剂敏感。

3. 发明申请

WO2015178508A1 NRF2-BASED CANCER TREATMENT AND DETECTION METHODS AND USES 审中-公开
标题翻译：基于NRF2的癌症治疗和检测方法和用途
公开(公告)号：WO2015178508A1
公开(公告)日：2015-11-26
申请号：PCT/JP2015/065702
申请日：2015-05-21
申请人： CANBAS CO., LTD.
发明人： MINE, Naoki , KAWABE, Takumi
IPC分类号： G01N33/574 , A61K38/00 , A61P35/00 , G01N33/53
CPC分类号： G01N33/57484 , A61K35/13 , A61K38/08 , A61K38/10 , A61K38/465 , C12Q1/6886 , C12Q2600/156 , C12Q2600/158 , G01N33/574
摘要： Disclosed herein, inter alia, are methods and uses for treating a cancer in a subject. In various embodiments, a method or use includes measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2), or an NRF2 target gene, in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the amount of NRF2 in the sample or in the subject having cancer, then comparing the amount of NRF2 determined, or NRF2 target gene determined, to a baseline or reference amount of NRF2 or NRF2 target gene. If the amount of NRF2 or NRF2 target gene in the sample or in the subject having cancer is less than the baseline or reference amount of NRF2 or NRF2 target gene, the subject having the cancer may be or is treated with a peptide or peptidomimetic sequence set forth herein, such as P1, P2, P3, P4, P5, P6 (SEQ ID NO:1) or P6, P5, P4, P3, P2, P1 (SEQ ID NO:2), e.g., CBP501.
摘要翻译：本文公开了尤其是用于治疗受试者中的癌症的方法和用途。在各种实施方案中，一种方法或用途包括测量患有癌症的候选受试者或来自候选受试者的癌症样本的核因子红系2相关因子2（NRF2）或NRF2靶基因的表达，并确定量的NRF2在患有癌症的受试者中，然后将确定的NRF2的量或所确定的NRF2靶基因与NRF2或NRF2靶基因的基线或参考量进行比较。如果样品或具有癌症的受试者中的NRF2或NRF2靶基因的量小于NRF2或NRF2靶基因的基线或参考量，则具有癌症的受试者可以被肽或肽模拟序列组例如P1，P2，P3，P4，P5，P6（SEQ ID NO：1）或P6，P5，P4，P3，P2，P1（SEQ ID NO：2），例如CBP501。

4. 发明申请

WO2004089396A3 ANTI-FUNGAL PEPTIDOMIMETICS 审中-公开
标题翻译：抗真菌药物
公开(公告)号：WO2004089396A3
公开(公告)日：2005-01-06
申请号：PCT/IB2004001523
申请日：2004-04-07
申请人： CANBAS CO LTD , KAWABE TAKUMI , KOBAYASHI HIDETAKA
发明人： KAWABE TAKUMI , KOBAYASHI HIDETAKA
IPC分类号： A01N37/46 , A01N43/00 , A61K31/00 , A61K38/04 , A61K38/08 , A61K45/06 , A61P31/10 , C07K5/06 , C07K5/08 , C07K5/10 , C07K7/06 , C07K7/08 , C12Q1/18
CPC分类号： C07K7/06 , A01N37/46 , A01N43/00 , A61K31/00 , A61K38/04 , A61K38/08 , A61K45/06 , C07K5/06191 , C07K5/0827 , C07K5/1027 , C07K7/08 , C12Q1/18 , A61K2300/00
摘要： The invention relates to compounds including peptides and peptidomimetics having anti-fungal activity alone, and in combination with other agents that have anti-fungal activity. The invention includes the use of cell cycle G2 checkpoint abrogators as anti-fungal agents, such as anti-fungal medicine.
摘要翻译：本发明涉及包含肽和肽模拟物的化合物，其具有单独的抗真菌活性，并且与具有抗真菌活性的其它试剂组合。本发明包括使用细胞周期G2检查点清除剂作为抗真菌剂，例如抗真菌药物。

5. 发明申请

WO0121771A3 COMPOSITIONS AND METHODS FOR INHIBITING G2 CELL CYCLE ARREST AND SENSITIZING CELLS TO DNA DAMAGING AGENTS 审中-公开
标题翻译：将G2细胞周期和致敏细胞抑制在DNA损伤剂上的组合物和方法
公开(公告)号：WO0121771A3
公开(公告)日：2002-02-14
申请号：PCT/IB0001438
申请日：2000-09-21
申请人： CANBAS CO LTD , SUGANUMA MASASHI , KAWABE TAKUMI
发明人： SUGANUMA MASASHI , KAWABE TAKUMI
IPC分类号： G01N33/50 , A61K31/506 , A61K31/704 , A61K33/24 , A61K35/76 , A61K38/00 , A61K38/04 , A61K45/00 , A61K48/00 , A61P35/00 , A61P43/00 , C07H15/252 , C07K14/16 , C07K14/47 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/12 , C12N9/16 , C12N9/99 , C12N15/09 , C12N15/11 , C12N15/62 , C12Q1/48 , G01N33/15 , G01N33/53 , G01N33/566 , G01N33/574 , G01N33/68
CPC分类号： C07K14/4738 , A61K38/00 , A61K48/00 , C07K2319/00
摘要： The invention provides compositions and methods for inhibiting Chk1 and/or Chk2 kinases. Also provided are compositions and methods for inhibiting G2 cell arrest checkpoint, particularly in mammalian, e.g., human, cells. The compositions and methods of the invention are also used to treat disorders of cell growth, such as cancer. In particular, the invention provides methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA damaging agents and treatments. Also provided are methods for screening for compounds able to interact with, e.g., inhibit, enzymes involved in the G2 cell cycle arrest checkpoint, such as Chk1 and/or Chk2/Cds1 kinase.
摘要翻译：本发明提供了用于抑制Chk1和/或Chk2激酶的组合物和方法。还提供了用于抑制G2细胞停滞检查点的组合物和方法，特别是在哺乳动物例如人的细胞中。本发明的组合物和方法也用于治疗诸如癌症的细胞生长障碍。特别地，本发明提供了选择性地使G1检查点受损的癌细胞对DNA损伤剂和治疗敏感的方法。还提供了筛选能够与例如Chk1和/或Chk2 / Cds1激酶参与的G2细胞周期停滞检查点相关的化合物例如抑制化合物的方法。

6. 发明申请

WO2005014856A1 SENSITIVITY TEST TO PREDICT EFFICACY OF ANTI-CANCER THERAPIES 审中-公开
标题翻译：灵敏度测试以预防抗癌治疗效果
公开(公告)号：WO2005014856A1
公开(公告)日：2005-02-17
申请号：PCT/IB2004/002792
申请日：2004-08-06
申请人： CANBAS CO., LTD. , KAWABE, Takumi , KOBAYASHI, Hidetaka
发明人： KAWABE, Takumi , KOBAYASHI, Hidetaka
IPC分类号： C12Q1/68
CPC分类号： G01N33/5011 , A61K31/4745 , A61K33/24 , A61K45/06 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/142 , G01N33/502 , G01N2800/52 , A61K2300/00
摘要： The present disclosure provides methods for determining the sensitivity of cancerous cells to various anti-cancer therapies and predicting the efficacy of these therapies. Specifically, the present disclosure provides methods for predicting the efficacy of one or more candidate anti-cancer therapies in a patient, based on determining the sensitivity of the patient's cancerous cells after exposure to candidate anti-cancer therapies in vitro. The disclosure further provides methods for predicting the efficacy of candidate anti-cancer therapies by using an in vitro sensitivity test of the patient's cancerous cells and a surrogate in vivo efficacy test of the patient's cancerous cells grafted into a surrogate host. The disclosure further provides methods for selecting the most efficacious anti-cancer therapy(s) for a patient, thereby avoiding ineffective or unnecessary treatments.
摘要翻译：本公开提供了确定癌细胞对各种抗癌疗法的敏感性并预测这些疗法的功效的方法。具体地，本公开提供了基于在体外暴露于候选抗癌疗法之后确定患者癌细胞的灵敏度来预测患者中一种或多种候选抗癌疗法的功效的方法。本公开进一步提供了通过使用患者癌细胞的体外敏感性试验和接种到替代宿主中的患者癌细胞的替代体内功效试验来预测候选抗癌疗法的功效的方法。本公开还提供了选择用于患者的最有效的抗癌疗法的方法，从而避免无效或不必要的治疗。

7. 发明申请

WO2004089396A2 ANTI-FUNGAL COMPOUNDS AND METHODS OF USE 审中-公开
标题翻译：抗真菌化合物及其使用方法
公开(公告)号：WO2004089396A2
公开(公告)日：2004-10-21
申请号：PCT/IB2004/001523
申请日：2004-04-07
申请人： CANBAS CO., LTD. , KAWABE, Takumi , KOBAYASHI, Hidetaka
发明人： KAWABE, Takumi , KOBAYASHI, Hidetaka
IPC分类号： A61K38/16
CPC分类号： C07K7/06 , A01N37/46 , A01N43/00 , A61K31/00 , A61K38/04 , A61K38/08 , A61K45/06 , C07K5/06191 , C07K5/0827 , C07K5/1027 , C07K7/08 , C12Q1/18 , A61K2300/00
摘要： The invention relates to compounds including peptides and peptidomimetics having anti-fungal activity alone, and in combination with other agents that have anti-fungal activity. The invention includes the use of cell cycle G2 checkpoint abrogators as anti-fungal agents, such as anti-fungal medicine.
摘要翻译：本发明涉及包含肽和肽模拟物的化合物，其具有单独的抗真菌活性，并且与具有抗真菌活性的其它试剂组合。本发明包括使用细胞周期G2检查点清除剂作为抗真菌剂，例如抗真菌药物。

8. 发明申请

WO2017069291A1 PEPTIDES AND PEPTIDOMIMETICS IN COMBINATION WITH T CELL ACTIVATING AND/OR CHECKPOINT INHIBITING AGENTS FOR CANCER TREATMENT 审中-公开
标题翻译：肽联合T细胞激活和/或检查点抑制剂治疗癌症的肽和多肽联合治疗剂
公开(公告)号：WO2017069291A1
公开(公告)日：2017-04-27
申请号：PCT/JP2016/082500
申请日：2016-10-24
申请人： CANBAS CO., LTD.
发明人： KAWABE, Takumi
IPC分类号： C07K7/06 , A61K33/24 , A61K39/395 , A61P35/00 , C07K7/08 , C07K16/28
CPC分类号： A61K38/10 , A61K31/282 , A61K33/24 , A61K38/05 , A61K38/08 , A61K39/39558 , A61K2039/505 , C07K14/00 , C07K16/00 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K2317/31 , C07K2317/76 , C07K2319/10
摘要： This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells, and combinations of T cell activating agents and/or an immune checkpoint inhibitors with and without peptides and peptidimimetics. The invention compounds and combinations can be used to inhibit cell growth, such as treat a tumor or cancer.
摘要翻译：本发明提供了可用于治疗细胞增殖性病症的肽和肽模拟物的化合物，所述细胞增殖性病症例如与良性和恶性肿瘤细胞相关的那些以及T细胞活化剂和/或免疫检查点的组合具有和不具有肽和肽模拟物的抑制剂。本发明化合物和组合可用于抑制细胞生长，如治疗肿瘤或癌症。

9. 发明申请

WO2009031040A3 COMPOUNDS WITH ANTI-CANCER ACTIVITY 审中-公开
标题翻译：具有抗癌活性的化合物
公开(公告)号：WO2009031040A3
公开(公告)日：2009-05-14
申请号：PCT/IB2008003036
申请日：2008-04-11
申请人： CANBAS CO LTD , KAWABE TAKUMI , ISHIGAKI MACHIYO , SATO TAKUJI , YAMAMOTO SAYAKA , HASEGAWA YOKO
发明人： KAWABE TAKUMI , ISHIGAKI MACHIYO , SATO TAKUJI , YAMAMOTO SAYAKA , HASEGAWA YOKO
IPC分类号： C07D401/12 , A61K31/4439 , A61K31/4725 , A61K31/496 , A61P35/00 , C07D207/452 , C07D401/14 , C07D403/04 , C07D405/14 , C07D417/12
CPC分类号： A61K31/4439 , A61K31/4725 , A61K31/496 , C07D207/452 , C07D207/50 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/14 , C07D417/12
摘要： Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.
摘要翻译：提供了新型取代的唑类二恶英，其杀死细胞，抑制细胞增殖，抑制细胞生长，消除细胞周期G2检查点和/或引起适应G2细胞周期停滞。提供了制备和使用本发明化合物的方法。本发明提供取代的唑类二恶英以治疗细胞增殖障碍。本发明包括使用取代的唑类二聚体来选择性地杀死或抑制癌细胞而无需额外的抗癌治疗。本发明包括使用细胞周期G2-检查点 - 取代的取代唑类二恶英来选择性地使癌细胞对DNA损伤试剂，治疗和/或其它类型的抗癌试剂敏感。

10. 发明申请

WO2004112820A3 PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY 审中-公开
公开(公告)号：WO2004112820A3
公开(公告)日：2004-12-29
申请号：PCT/IB2004/002591
申请日：2004-06-25
申请人： CANBAS CO., LTD. , KAWABE, Takumi , KOBAYASHI, Hidetaka
发明人： KAWABE, Takumi , KOBAYASHI, Hidetaka
IPC分类号： A61K38/08
摘要： The invention provides compounds having immune-modulating and/or anti-inflammatory and/or anti-viral activity, wherein compounds of the invention include peptides and peptidomimetics. The invention further provides methods of using immune-modulating and/or anti-inflammatory and/or anti-viral compounds of the invention. In particular, the invention provides methods for treating a disease related to an immune disorder or inflammation or viral infection by administering an amount of a G2-checkpoint-abrogating peptide or peptidomimetic sufficient to inhibit the disease.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式